The Board of Directors at Boule Diagnostics has today appointed Johan Folkunger, Chief Executive Officer, effective June 22, 2026. Johan Folkunger succeeds Simonetta Tumbiolo, who has been serving as Interim CEO.
Johan has extensive international leadership experience from the healthcare and medtech sector, spanning senior executive roles, CEO positions, and board appointments in listed and private companies. Most recently, Johan served as Group CEO of DNV Imatis, and has previously held CEO and executive roles within companies such as SpectraCure and Philips, including as CEO of Philips Sweden. He has also held the position of Executive Vice President at MedCap AB.
In addition to executive leadership roles, Johan has broad board experience, including serving as Chair of the Board and board member in multiple healthcare and technology companies.
The Chair of the Board, Torben Jörgensen, comments:
“We are very pleased to welcome Johan Folkunger as CEO of Boule Diagnostics. He brings a rare combination of strategic leadership, operational execution, and deep industry experience from both global corporations and growth companies. The Board is confident that he is well positioned to lead Boule going forward.
I would also like to thank Simonetta Tumbiolo for her strong commitment and enthusiasm in stepping in as Interim CEO, ensuring continuity during an important transition period.”
Johan Folkunger, incoming CEO, comments
“I am pleased to be joining Boule Diagnostics and look forward to working with the Board and the organization to support the Company’s continued development.”